4.8 Article

Detection and localization of surgically resectable cancers with a multi-analyte blood test

期刊

SCIENCE
卷 359, 期 6378, 页码 926-+

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aar3247

关键词

-

资金

  1. Lustgarten Foundation for Pancreatic Cancer Research
  2. Virginia and D. K. Ludwig Fund for Cancer Research
  3. Conrad N. Hilton Foundation
  4. Commonwealth Fund
  5. John Templeton Foundation
  6. Clinomics Program
  7. Mayo Clinic Center for Individualized Medicine
  8. Mayo Clinic Biobank
  9. Sol Goldman Center for Pancreatic Cancer Research
  10. Michael Rolfe Pancreatic Cancer Research Foundation
  11. Benjamin Baker Scholarship
  12. Gray Foundation
  13. Marcus Foundation
  14. Honorable Tina Brozman Foundation
  15. Burroughs Wellcome Career Award for Medical Scientists
  16. Doris Duke Charitable Foundation [2014107]
  17. National Institutes of Health [P50-CA62924, P50-CA102701, CA06973, CA152753, GM-07309, U01CA200469, U01CA152753]

向作者/读者索取更多资源

Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据